Poliwogg

Disease-Specific Indexes Poliwogg publishes and licenses disease-specific indexes (the “Poliwogg Indexes”), which are designed to underlie financial instruments such as swaps, forward and futures contracts, options, exchange traded funds, and other structured products. Each individual Index is published monthly, and tracks the average cost per patient in the US of a particular disease or condition for the preceding twelve months. The source data for the Indexes is comprehensive and unique paid claims data. Bringing together informed analysis and big data, Poliwogg delivers innovative and proprietary indexes that enhance and complete the spectrum of sector based investment and hedging tools. Poliwogg believes that better price discovery will allow for better transfer and mitigation of risk, with the potential to improve the efficiency of the entire sector. The first disease-specific Poliwogg Index tracks Type 2 Diabetes, and represents the cost of treating one patient for one year suffering from Type 2 Diabetes. Additional Index releases covering different maladies will occur throughout 2017. Poliwogg Equity Indexes Poliwogg applies metrics specific to biotechnology and pharmaceuticals that are not applicable to other sectors or industries, resulting in highly idiosyncratic performance characteristics. Indexes are comprised of companies that are principally engaged in the US health care sector, with a strong emphasis on the dynamic small/mid-capitalization biotechnology segment. -Poliwogg Medical Breakthroughs Index (TICKER: PMBI) PMBI has been Licensed ALPS and is the basis for The ALPS Medical Breakthroughs Exchange Traded Fund -Poliwogg Healthcare Innovation Index (TICKER: PHIX) PHIX has been licensed to SmartTrust® as the basis for the SmartTrust Healthcare Innovations Unit Investment Trust -Poliwogg Biopharma Merger & Acquisition Index (TICKER: PBMA)